Recon: Pfizer to acquire Biohaven for $11.6B; Emergent’s manufacturing problems worse than previously known
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy